Lipidomics-driven DDS Company

Engineering lipid signaling pathways
to deliver better medicines.

Curiosa Bioscience develops innovative Drug Delivery Systems grounded in lipidomic insight — turning a foundational language of the cell into a clinical advantage for patients.

Explore SNAP Technology View Pipeline
01 / MISSION

Lipid signaling, reimagined for delivery.

Lipids are not merely structural —
they are a foundational language
through which the cell speaks.

Curiosa Bioscience investigates cellular lipid signaling pathways to develop innovative Drug Delivery Systems grounded in lipidomic insight. By understanding how lipids communicate, traffic, and accumulate within tissue, we design molecules that move with — rather than against — the body.

Our DDS platforms address the most demanding pharmaceutical challenges across therapeutic areas: penetrating the blood–brain barrier, achieving organ-level selectivity, enabling oral peptide bioavailability, and sustaining therapeutic concentration over weeks and months.

02 / PROPRIETARY PLATFORM
SNAP Technology
Smart · Navigator · Anchoring · Platform
Architecture
One molecule. Three engineered components.
• Receptor targeting • Payload protection • Release control • Controllable release • Payload specific • Biocompatible • Small Molecules • Peptides • Nucleic Acids · Proteins Payload Small Molecules Peptides Nucleic Acids Proteins Targeting Lipid Functional Linker Diverse Payload

Curiosa's proprietary lipid-linker conjugation platform — engineered for target delivery, controlled release, payload protection, and on/off safety mitigation. Built from in-house lipid and linker libraries, designed to align with target product profiles across small molecules, peptides, and biomolecules.

01
Target Delivery

Receptor, transporter, BBB, organ & cell-level targeting

02
Release Control

Slow release for intended duration; conditional release on environmental cues

03
Payload Protection

Complex structures shielding API from harsh in-vivo conditions

04
On & Off

Safety mitigation while in inactive prodrug-state form

03 / PERFORMANCE INDEX
49,725
Lipids in CRS Library
In-house lipid library built by extracting data from public databases and Curiosa's proprietary and academic sources, continuously refined and enhanced over time.
49
SNAP Molecules Synthesized
After selecting lipids from the library that match the Target Product Profile, we synthesized them with drug molecules — producing 49 SNAP molecules to date.
472
Formulations Tested
An average of 10 formulations per molecule, evaluating a wide range of dosage forms tailored to the respective Target Product Profiles.
4
Core Platforms
SNAP Technology, Nanora, EnDura, and CRS Lipid Library — Curiosa's proprietary platforms powering every program in our pipeline.
04 / PIPELINE
Code Modality DS Platform DP Platform Dosage Indication Progress
CRS-001N Peptide SNAP Nanora Oral Obesity
CRS-001E Peptide SNAP EnDura LAI (1W, 4W) Obesity
CRS-002N Peptide SNAP Nanora Oral Prostate cancer
CRS-002E Peptide SNAP EnDura LAI (4W) Prostate cancer
CRS-003N Peptide SNAP Nanora Oral Prostate cancer
CRS-004E Peptide SNAP EnDura LAI (1W) Inflammation
CRS-005E Small Molecule SNAP EnDura LAI (4W) Depression
CRS-006E Small Molecule SNAP EnDura LAI (1W) POPC
CRS-007E Small Molecule SNAP EnDura LAI (1M) Parkinson's
CRS-008E Small Molecule SNAP EnDura LAI (1M) Atopic dermatitis
Lead synthesis Lead optimization Formulation study In vivo study
05 / LEADERSHIP

Balanced expertise.

Curiosa's leadership combines the four pillars required to build a specialty DDS biopharma — Business Development, Drug Delivery Systems, Medicinal Chemistry, and Pharmacokinetics. Each leader brings deep, domain-specific competency across our value chain.

CEO
Wanju Kim
Business Development
  • Global Licensing & Out-licensing — Structuring DDS platform deals with multinational pharma partners
  • Strategic Partnership Design — Co-development, technology transfer, and joint pipeline agreements
  • Investor Relations — Capital strategy and stakeholder communication across funding stages
  • Commercial Translation — Bridging scientific assets and market opportunity
CTO
Sangwook Woo
Drug Delivery System
  • Lipid-Based Formulation — SMEDDS, Liquid Filled Hard Capsule, SLN, and long-acting injectable platforms
  • Process & Scale-up — From bench formulation to industrialized LBDDS manufacturing
  • CMC Development — Quality-by-design and regulatory-ready formulation strategy
  • Platform Engineering — Architecting Nanora and EnDura drug product platforms
CSO
Sujin Lee
Medicinal Chemistry
  • Lipid & Linker Design — In-house library design and synthesis for SNAP Technology
  • Lipid-Drug Conjugation — Small molecule, peptide, and biomolecule conjugation chemistry
  • Structure-Property Optimization — Tuning lipophilicity, stability, and release kinetics
  • Novel Modality Discovery — Screening lipid analogue drug candidates
CCO
Taewhan Kim
Pharmacokinetics
  • PK / PD Modeling — Quantitative translation from preclinical to human dosing
  • Bioavailability Strategy — Oral absorption, BBB penetration, and lymphatic uptake
  • In Vivo Study Design — Pharmacokinetic study planning and data interpretation
  • Clinical Pharmacology — Translational strategy for first-in-human readiness
06 / CONTACT

Let's build.

Partner with us on the next generation of lipidomic DDS.

Whether you're exploring co-development, platform licensing, or strategic collaboration — we'd be glad to hear from you.

Business Development
jay.kim@curiosa.co.kr
Location
Republic of Korea